<DOC>
	<DOCNO>NCT00304720</DOCNO>
	<brief_summary>Primary Objective : A . To determine whether stable allogeneic hematopoietic engraftment safely establish patient receive non-myeloablative allogeneic SCT match sibling donor , fludarabine low-dose TBI , pre- post-transplant immunosuppression tacrolimus MMF . B . To evaluate incidence grade II-IV GVHD associate treatment .</brief_summary>
	<brief_title>Tacrolimus MMF Post Grafting Immunosuppression After Conditioning With Flu TBI HLA Matched Family Donor</brief_title>
	<detailed_description>Conditioning regimen : 1 . Days - 4 -2 : Fludarabine 30 mg/m2/day IV . 2 . Day 0 : TBI 2.0 Gy 6-7 cGy/min linear accelerator , follow stem-cell infusion . TBI preferably administer 7:00 a.m. 1:00 p.m. avoid proximity tacrolimus/MMF administration . Immunosuppression : Day -3 : Start tacrolimus 0.06 mg/kg PO BID . Day 0 : Start MMF 15 mg/kg PO b.i.d . day 0 ( PM dose ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients AML , ALL , CML , CLL , myelodysplastic syndrome ( MDS ) , NHL , Hodgkin 's disease ( HD ) , myeloma , significantly high usual risk mortality conventional myeloablative allogeneic SCT due age comorbidities : Age ³ 50 year AML ALL complete remission &lt; 10 % blast bone marrow Age ³ 50 year MDS CML . Age &gt; 50 year lymphomas myeloma , fail chemotherapy candidate autologous transplant , fail prior autologous SCT . Patients age CLL lowgrade NHL . Patients CLL lowgrade NHL need fail least firstline treatment , alkylating agent , fludarabine 2chlorodeoxyadenosine ( 2CDA ) , antiCD20 monoclonal antibody rituximab . 2 . Patients hematological malignancy relapse prior autologous transplantation . 3 . Patients highrisk ( &gt; 60 % ) relapse autologous transplantation hematological malignancy may receive allogeneic transplant `` consolidative immunotherapy '' . Diagnoses include multiple myeloma , nonHodgkin 's lymphoma , Hodgkin 's lymphoma , AML , ALL MDS . Minimal duration autologous allogeneic transplant 4 week . 4 . Patients age hematologic malignancy treatable allogeneic SCT , , preexist medical condition , consider significantly increase risk transplant toxicity use highdose transplant regimen . 5 . Patients metastatic renal cell carcinoma . Must include good performance status ( Karnofsky score &gt; 60 % ) , active brain metastasis , life expectancy &gt; 6 month , absence bulky liver metastasis . Patients treat active diseasespecific protocol available . 6 . Patients malignant disease treatable allogeneic SCT may eligible protocol case case basis , approve principal investigator BMT attend physician group . 7 . Available HLAidentical sibling donor , phenotypically HLAmatched family member . 8 . Age &lt; 70 year . 1 . Patients hematological malignancy eligible curative autologous SCT : intermediate highgrade NHL chemosensitive first relapse . HD chemosensitive first relapse . 2 . Age &lt; 50 year eligible conventional myeloablative allogeneic SCT . 3 . Patients rapidly progressive intermediate high grade NHL , unless minimal disease state . 4 . Patients active uncontrolled CNS involvement malignancy . 5 . Fertile men woman unwilling use contraceptive technique 12 month follow treatment . 6 . Females pregnant . 7 . Patients HIV positive 8 . Organ dysfunction 1 . Left ventricle ejection fraction &lt; 35 % . 2 . DLCO &lt; 35 % predict , receive continuous supplementary oxygen . 3 . Liver function test : total bilirubin &gt; 2x upper limit normal , and/or transaminase &gt; 4x upper limit normal . 4 . Karnofsky score &lt; 50 patient &lt; 60 year , &lt; 70 patient age 60 69 year ( see appendix B ) . 5 . Creatinine clearance &lt; 60 ml/min . 6 . Patients hypertension poorly control antihypertensive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
</DOC>